![conference banner](/images/conference-banner.jpeg)
Abstract
Background: Autoimmune phenotypes are prevalent in major psychiatric disorders. Disequilibria of cellular processes occurring in the gastrointestinal (GI) tract likely contribute to immune dysfunction in psychiatric disorders. As the venue of a complex community of resident microbes, the gut in a homeostatic state equates with a functional digestive system, cellular barrier stability and properly regulated recognition of self and non-self antigens. When gut processes become disrupted as a result of environmental or genetic factors, autoimmunity may ensue.
Methods: Here, we review the issues pertinent to autoimmunity and the microbiome in psychiatric disorders and show that many of the reported immune risk factors for the development of these brain disorders are in fact related and consistent with dysfunctions occurring in the gut. We review the few human microbiome studies that have been done in people with psychiatric disorders and supplement this information with mechanistic data gleaned from experimental rodent studies.
Results: These investigations demonstrate changes in behavior and brain biochemistry directly attributable to alterations in the gut microbiome. We present a model by which autoantigens are produced by extrinsicallyderived food and microbial factors bound to intrinsic components of the gut including receptors present in the enteric nervous system.
Conclusion: This new focus on examining activities outside of the CNS for relevance to the etiology and pathophysiology of psychiatric disorders may require new modalities or a re-evaluation of pharmaceutical targets found in peripheral systems.
Keywords: Microbiota, schizophrenia, autism, psychosis, NMDA receptor, bacteria, virus, gluten, celiac disease, gut-brain axis.
Current Pharmaceutical Design
Title:The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders
Volume: 22 Issue: 40
Author(s): Emily G. Severance, Dag Tveiten, Lief H. Lindström, Robert H. Yolken and Karl L. Reichelt
Affiliation:
Keywords: Microbiota, schizophrenia, autism, psychosis, NMDA receptor, bacteria, virus, gluten, celiac disease, gut-brain axis.
Abstract: Background: Autoimmune phenotypes are prevalent in major psychiatric disorders. Disequilibria of cellular processes occurring in the gastrointestinal (GI) tract likely contribute to immune dysfunction in psychiatric disorders. As the venue of a complex community of resident microbes, the gut in a homeostatic state equates with a functional digestive system, cellular barrier stability and properly regulated recognition of self and non-self antigens. When gut processes become disrupted as a result of environmental or genetic factors, autoimmunity may ensue.
Methods: Here, we review the issues pertinent to autoimmunity and the microbiome in psychiatric disorders and show that many of the reported immune risk factors for the development of these brain disorders are in fact related and consistent with dysfunctions occurring in the gut. We review the few human microbiome studies that have been done in people with psychiatric disorders and supplement this information with mechanistic data gleaned from experimental rodent studies.
Results: These investigations demonstrate changes in behavior and brain biochemistry directly attributable to alterations in the gut microbiome. We present a model by which autoantigens are produced by extrinsicallyderived food and microbial factors bound to intrinsic components of the gut including receptors present in the enteric nervous system.
Conclusion: This new focus on examining activities outside of the CNS for relevance to the etiology and pathophysiology of psychiatric disorders may require new modalities or a re-evaluation of pharmaceutical targets found in peripheral systems.
Export Options
About this article
Cite this article as:
Severance G. Emily, Tveiten Dag, Lindström H. Lief, Yolken H. Robert and Reichelt L. Karl, The Gut Microbiota and the Emergence of Autoimmunity: Relevance to Major Psychiatric Disorders, Current Pharmaceutical Design 2016; 22 (40) . https://dx.doi.org/10.2174/1381612822666160914183804
DOI https://dx.doi.org/10.2174/1381612822666160914183804 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrinsic Disorder in the Core Proteins of Flaviviruses
Protein & Peptide Letters Recent Developments in Delivery of Nucleic Acid-Based Antiviral Agents
Current Pharmaceutical Design p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Biology of Mesenchymal Stem Cells
Current Rheumatology Reviews Oxidative stress and myocarditis
Current Pharmaceutical Design Novel Applications of Nanotechnology in Controlling HIV and HSV Infections
Current Drug Research Reviews Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science New Drug Targets for Hepatitis C and Other Flaviviridae Viruses
Infectious Disorders - Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Playing with Fire: Manipulation of Macrophage Proinflammatory Signal Transduction by the Intracellular Protozoan Toxoplasma gondii
Current Immunology Reviews (Discontinued) From Alpha to Omega with Aβ: Targeting the Multiple Molecular Appearances of the Pathogenic Peptide in Alzheimers Disease
Current Medicinal Chemistry Current Perspectives on Neurological Diseases: Experimental Models, Mechanisms of Disease and Treatments
CNS & Neurological Disorders - Drug Targets Atypical Cytotoxic Lesion and Hemorrhagic Involvement of the Corpus Callosum in Severe COVID-19 Infection
Current Medical Imaging The Association between Depression and Gastroesophageal Reflux based on Phylogenetic Analysis of miRNA Biomarkers
Current Medicinal Chemistry Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Safe Use of Sodium Dodecyl Sulfate (SDS) to Deactivate SARS-CoV-2: An Evidence-Based Systematic Review
Coronaviruses Synthesis, Molecular Docking and Evaluation of 3-{4-[2-amino-4-(substitutedphenyl)-2H-[1, 3] oxazin/thiazin-6-yl} 2-phenyl-3H-quinazolin-4-one Derivatives for their Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry